Muscle wasting is a major contributor to loss of mobility and independence due to ageing or illness. For patients with small appetites, it can be difficult to consume enough protein to maintain existing muscle mass.
Our juice-style drink concept with Lacprodan® BLG-100 is a new opportunity for manufacturers of oral nutrition supplements (ONS) targeting the dietary management of malnutrition and muscle loss – by developing appealing, alternatives to the traditional milky drinks that continue to be the primary offer to this segment.
Although juice-style ONS have been on the market for some time, there is much more potential to explore. Recent product launch history shows they still represent less than 4% of all market launches over the last five years[1].
With Lacprodan® BLG-100, it’s possible to go beyond the limits of existing market offerings.
A powerful protein source
Lacprodan® BLG-100 comprises 100% beta-lactoglobulin – a whey protein with an outstanding nutritional profile, that has a natural, high amount of essential amino acids, especially leucine.
The average protein content of existing juice-style ONS on the market is 4.2 g per 100 g1. Our inspirational juice-style drink contains:
- 7 g protein per 100 g
- 1.13 g leucine per 100 g
We’ve also adjusted the pH to reduce astringency and acidity, improving the taste experience. The stable, low viscosity contributes to a pleasant mouthfeel.
Lacprodan® BLG-100 authorized as a novel food
As of 21 December 2022, Arla Foods Ingredients has received final authorization from the European Commission (EC) for its beta-lactoglobulin ingredient, Lacprodan® BLG-100.
The authorization states that Lacprodan® BLG-100 is safe and suitable to use in food products in the EU. The ingredient is suitable for a variety of applications within sports nutrition and in food for special medical purposes (FSMP).
Lacprodan® BLG-100 is Arla Foods Ingredients’ first product to receive approval under the new Novel Food Regulations (EU) 2015/2283.
[1] Innova Market Insights, 2017-2022
